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Abstract
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Purpose—To evaluate patient-reported outcomes (PROs) for bladder cancer patients undergoing
neoadjuvant chemotherapy (NAC) prior to radical cystectomy (RC) using longitudinal data and
propensity-matched scoring analyses.
Methods—155 patients with muscle-invasive bladder cancer scheduled for RC completed the
European Organization for Research and Treatment of Cancer questionnaires, EORTC QLQ-C30,
EORTC QLQ-BLM30, Fear of Recurrence Scale, Mental Health Inventory and Satisfaction with
Life Scale within 4 weeks of surgery. A propensity-matched analysis was performed comparing
pre-surgery PROs among 101 patients who completed NAC versus 54 patients who did not receive
NAC. We also compared PROs pre- and post-chemotherapy for 16 patients who had data available
for both time points.
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Results—In propensity-matched analysis, NAC-treated patients reported better emotional and
sexual function, mental health, urinary function and fewer financial concerns compared to those
that did not receive NAC. Longitudinal analysis showed increases in fatigue, nausea and appetite
loss following chemotherapy.
Conclusion—Propensity-matched analysis did not demonstrate a negative effect of NAC on
PRO. Several positive associations of NAC were found in the propensity-matched analysis,
possibly due to other confounding differences between the two groups or actual clinical benefit.
Longitudinal analysis of a small number of patients found small to modest detrimental effects
from NAC similar to toxicities previously reported. Our preliminary findings, along with known
survival and toxicity data, should be considered in decision-making for NAC.
Keywords
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Patient-reported outcomes; Patient-centered research; Health-related quality of life; Bladder cancer

Introduction
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For patients with muscle-invasive bladder cancer (MIBC), cisplatin-based, neoadjuvant
chemotherapy (NAC) given prior to radical cystectomy (RC) is associated with an overall
survival benefit and is considered standard of care for patients who are eligible for such
regimens [1–3]. Despite level 1 evidence, utilization of NAC has historically been low,
perhaps due to concerns of overtreatment, tolerability and toxicity [4, 5]. Although
comparisons of toxicity were measured in the randomized trials of NAC, we are not aware of
any patient-reported outcomes (PRO) assessing comparative differences in health-related
quality of life for those managed with or without NAC, or the longitudinal effects of NAC
[6–9].
We therefore initiated a prospective PRO study for patients undergoing RC that included
general and disease-specific measures [10]. The main objective of the overall study is to
examine the impact of RC; therefore, a pre-surgical baseline assessment was performed on
all patients. In conducting this study, we have also obtained pre-NAC data on a subset of
patients. As such, the current study had two objectives: (1) perform a propensity-matched
scoring analysis comparing post-NAC HRQoL prior to RC to that of patients who did not
receive NAC; and (2) compare quality-of-life scores pre- and post-NAC.

Methods
Patient cohort

Author Manuscript

This study was approved by the institutional review board at Memorial Sloan Kettering
Cancer Center. All patients with a diagnosis of bladder cancer who were scheduled for RC
between September 2008 and July 2014 were approached in our urology clinic for
enrollment in a prospective, longitudinal PRO study. Patients had to be ≥ 18 years of age,
English speaking and able to provide informed consent. Patients were excluded if they were
not able to follow up at our institution or had distant metastatic disease at diagnosis. All
enrolled patients were asked to complete a baseline questionnaire within 4 weeks of the
scheduled RC. If patients were recruited to the study prior to receiving NAC, they were
World J Urol. Author manuscript; available in PMC 2019 November 03.
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asked to complete questionnaires pre-NAC as well as post-NAC/pre-cystectomy. Receiving
NAC was a shared decision between treating physician and patient.
Patient-reported outcome variables—The European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQC30) version 3.0 is a
validated instrument to measure the PRO in cancer patients [11]. It is a 30-item
questionnaire with six functional domains: physical, role, emotion, social, cognition and
global functioning. There are three symptom domains: fatigue, pain and emesis, and six
single-item symptom questions measuring dyspnea, insomnia, appetite loss, diarrhea,
constipation and financial concerns. A high score for a functional domain is considered a
better level of functioning, whereas higher scores for a symptom domain or item are
considered to be less favorable. A change in ten points or more over time is considered to be
clinically significant [12].

Author Manuscript

The EORTC QLQ-BLM30 is a 30-item instrument designed for patients with MIBC and is
intended for use as a supplementary module to EORTC QLQ-C30 [13]. There are seven
domains: urinary symptoms, urostomy problems, bloating/flatulence, body image
dissatisfaction, worry (future perspectives), catheter problems and sexual dysfunction.
Higher scores reflect worse symptomatology. For the purposes of the present study, domains
for urostomy problems and catheter problems were not relevant to patients, and thus were
not included in our analysis.

Author Manuscript

We used three additional validated questionnaires to assess the psychological well-being of
patients prior to RC. The Satisfaction with Life Scale is a five-item measure of global
satisfaction with life [14]. Higher scores are indicative of more satisfaction. The Fear of
Recurrence Questionnaire is a 22-item measure that was initially designed in breast cancer
patients [15]. A higher total score reflects a higher fear of recurrence. The Mental Health
Inventory is a 5-item questionnaire derived from the 38-item Mental Health Inventory Scale
[16]. A higher total score reflects favorable mental health.
Derivation of propensity scores

Author Manuscript

Because NAC was not a randomized treatment, but is a treatment that has certain clinical
selection criteria, we used propensity scoring to account for differences between patients
who did and did not receive NAC [17]. Propensity scores were created using logistic
regression analysis to identify demographic and clinical variables associated with receipt of
NAC [18]. Demographic variables included were age, gender, ethnicity, employment status
and marital status. Clinical measures collected prior to enrollment included age-adjusted
Charlson Comorbidity Index (CCI) [19], American Society of Anesthesiologists (ASA)
score, receipt of intravesical therapy, receipt of pelvic radiotherapy, pre-operative glomerular
filtration rate (GFR) calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation and receipt of NAC. Comorbidities were divided to
categorize each condition per patient according to the CCI: cardiovascular disease,
peripheral vascular disease, cerebrovascular disease, dementia, chronic obstructive
pulmonary disease (COPD), peptic ulcer disease, diabetes, moderate to severe chronic
kidney disease, hemiplegia, other hematological or solid cancer, chronic liver disease and
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neurologic dysfunction. For our main analyses, we used the propensity score as a covariate,
entered into regression models prior to testing the effects of NAC. We further considered an
alternative approach to propensity adjustment, segmenting the sample into quintiles based on
propensity scores. This allowed us to compare more tightly matched NAC and non-NAC
patients within propensity quintiles. Some of the quintile groups were small using this
approach, so we chose not to report it as a primary analysis. However, findings were
suggestive of future research possibilities, as summarized in “Discussion”.
Statistical considerations

Author Manuscript

SPSS v25.0.0 was used for all statistical testing [20]. Propensity scores were used as
covariates for group comparisons and the standardized regression coefficients were
calculated to represent the extent to which the two groups differed in standard deviation
units. As this was an exploratory analysis of a subset of patients from our original protocol,
we included all findings with exact statistical significance in both our longitudinal and
propensity scoring analyses.

Results

Author Manuscript

At baseline, 155 of 232 (67%) patients with MIBC completed the questionnaires prior to
RC. 101 of 155 (65%) MIBC patients received NAC. Patient characteristics and comparisons
of those who did and did not receive NAC are presented in Table 1. In terms of
demographics, these groups were similar in all regards except for age. Compared to patients
who did not receive NAC, patients who did receive NAC were younger (median 67 vs. 73
years old, p < 0.001). Although groups were similar in terms of age-adjusted comorbidity
scores, we noted that the NAC group was less likely to have been diagnosed with chronic
kidney disease (4% vs. 15%, p = 0.016) or with other malignancies (13% vs. 26%, p =
0.041), but were more likely to have been diagnosed with peptic ulcer disease (35% vs. 17%,
p = 0.018). Eighty-seven of the 101 (86%) patients who underwent NAC treatment received
gemcitabine and cisplatin.
Propensity-matched scoring analysis
Propensity to receive NAC was associated with younger age [odds ratio (OR) = 0.934 per
year, p < 0.001] and a trend toward not having received prior pelvic radiation (OR = 0.323, p
= 0.067); however, all demographic and clinical variables used to derive propensity scores
were used in the regression analysis.

Author Manuscript

Table 2 shows pre-surgery PRO for patients who did and did not receive NAC. The results of
the linear regression analysis using propensity score as a covariate are presented in Table 3.
Patients who received NAC reported better emotional function, fewer urinary symptoms and
better scores on the Mental Health Inventory. There was also a trend toward fewer financial
problems and lower levels of sexual dysfunction associated with NAC.
Longitudinal analysis
Sixteen patients who received NAC completed both pre- and post-NAC questionnaires
(Table 4). Patients who received NAC reported an increase in fatigue, nausea and appetite
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loss. There was also a trend toward worse dyspnea and body image satisfaction, a decline in
global health status, social function and financial problems.

Discussion

Author Manuscript

In terms of toxicity of NAC, the Southwest Oncology Group 8710, which compared three
cycles of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC), followed by RC to
RC alone, found a 33% rate of grade 4 myelosuppression and 17% rate of gastrointestinal
toxicity and no attributable deaths [7]. The International Collaboration of Trialists study
assigned patients to three cycles of cisplatin, methotrexate and vinblastine or no
chemotherapy prior to definitive treatment. They reported 16% grade 3 or 4
myelosuppression and common nausea despite antiemetics (percent not reported), and five
patients (1%) died from toxicity. In the current study, nearly all patients in the NAC group
received gemcitabine and cisplatin, which has been shown to have equivalent response rates
with less toxicity compared to MVAC [21].
However, we believe that toxicity and PRO should be considered distinct end points. In fact,
PROs are often more accurate than clinician-assessed toxicity [22, 23]. In analysis of both
propensity-adjusted group differences and pre–post comparisons, NAC was found to have no
detrimental effect on the majority of PRO items and domains measured, including physical
function, pain, fear of recurrence and satisfaction with life.

Author Manuscript

Considering the lack of data on longitudinal PRO for neoadjuvant chemotherapy, we thought
it was important to examine changes in the available 16 patients despite limitations in
statistical power. We found that patients who received NAC reported statistically and
clinically significant increases in fatigue, nausea and appetite loss as would be expected
from reported toxicities. NAC was also associated with a trend toward worsening global
health status, social function, dyspnea and body image. Ideally, a larger percentage of
patients would have available pre- and post-NAC PRO data.

Author Manuscript

In our propensity scoring analysis, there was a positive association between receipt of NAC
and emotional function, urinary symptoms, financial problems and mental health. However,
these differences were small to modest and no differences were found in the majority of
items measured. Although propensity matching controlled for age differences between the
two groups, we acknowledge that in this non-randomized comparison, clinical selection
criteria are very important and could introduce unmeasured confounding differences, such as
unmeasured health conditions or health of sexual partners, which can explain the positive
PRO effects of NAC. Alternatively, patients may feel encouraged about successfully
completing chemotherapy and the positive association between NAC and improved survival.
In an exploratory analysis, we also performed a linear regression treating propensity as a
categorical variable rather than as a linear covariate. Patients were divided into quintiles
according to propensity, from least to most likely to receive NAC. Although limited by small
sample sizes within groups, propensity matching in this way provided a tighter control, by
forcing comparisons of NAC and non-NAC patients within each quintile. Regression
analyses were repeated for all of the dependent variables listed in Table 3, controlling for
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propensity group and testing propensity group by NAC interaction effects. The results
demonstrated two distinct patterns. For variables related to physical symptoms, NAC
patients tended to do worse than quintile-matched non-NAC patients on measures of specific
symptoms, including diarrhea, constipation, nausea, fatigue and sexual interest.
Alternatively, the impact of NAC on global and psychological variables depended upon each
group’s relative propensity to receive NAC. Specifically, receiving NAC was associated with
better emotional functioning, less worry about recurrence and greater life satisfaction in the
quintile second-most likely to receive NAC. In contrast, for patients in the second-least
likely quintile, NAC was associated with worse mental health and more negative future
perspective. The middle quintile showed mixed association between psychological outcomes
and NAC, with worse role functioning but better emotional functioning. No group-specific
effects were evident in either the first or the last propensity quintiles. Although further
research is necessary, these analyses suggest that the quality-of-life effects of NAC could be
predicted by more patient-centric criteria involving the patients’ profile of demographic
clinical characteristics.

Author Manuscript

This study has several limitations. We believe our overall response rate of 66% reflects the
challenges of conducting a comprehensive PRO assessment prior to major surgery. Similar
to other PRO studies, our results reflect the responses of patients who were willing and able
to participate. It is important to note that not all patients are eligible to receive NAC and
selection of patients incorporates multiple variables, some of which may not have been
adequately captured. Although we performed a detailed propensity analysis of patient
variables, we acknowledge that the non-randomized nature of treatment could have
introduced biases not considered in the propensity scoring.
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This is one of the first studies to compare PRO for NAC prior to RC. In the current study, we
found small to modest detrimental PROs in our longitudinal analysis that mirrors known
toxicities, but no negative PROs in our propensity-matched analyses. There may be specific
subsets of patients for whom NAC has positive and negative impacts to PROs. Further
follow-up will allow us to examine NAC effects post-operatively. We believe these
preliminary findings further support the use of NAC in eligible patients. We emphasize that
receipt of NAC should be a shared decision between health-care providers and patients,
considering the clinical benefits and toxicity outcomes as well as PROs.
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76%
51%
95%
29%

Employed

Caucasian

GFR<60

15 (17%)
75 (83%)

<4

4

Number of cycles (missing n = 11)

56%

54%

≥2

Married

52%

98%

37%

65%

44%

28 (26, 30)

17%

28%
27 (25,31)

83%

46%

<2

Age-adjusted Charlson Comorbidity Index

Median BMI, kg/m2 (IQ range)

Female

Male

73 (67, 78)

54

No neoadjuvant chemotherapy

72%

67 (60, 72)

Median age, yrs (IQ range)

Gender

101

Number of patients

Neoadjuvant chemo-therapy

0.004

NS

NS

NS

NS

NS

NS

< 0.001

P value
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101
101
101
101
101
101
101
101
101
101
101
99
95
95
94
68
99

Cognitive function
Social function
Fatigue*
Nausea/vomiting*
Pain*
Dyspnea*
Insomnia*
Appetite loss*
Constipation*
Diarrhea*
Financial problems*
Urinary symptoms*
Future perspectives
Bloating/flatulence*
Body image satisfaction
Sexual dysfunction*
Fear of recurrence*
Mental Health Inventory
Satisfaction with life

Fear of Recurrence Scale

Mental Health Inventory

Satisfaction with Life Scale

A higher score on these domains/items reflects worse quality of life

*

101

Emotional function

98

100

101

Role function

EORTC QLQ-BLM30

101

Physical function

Mean (SD)

26 (7)

22 (4)

78 (14)

47 (22)

76 (26)

18 (18)

53 (26)

24 (19)

14 (24)

7 (16)

17 (23)

13 (22)

26 (26)

13 (19)

10 (21)

6 (14)

26 (20)

74 (25)

85 (18)

77 (18)

83 (24)

90 (15)

72 (20)

53

54

53

38

42

43

43

54

51

53

53

54

54

54

54

54

54

53

53

53

54

54

53

26 (6)

22 (5)

77 (15)

52 (25)

80 (24)

17 (17)

45 (31)

35 (23)

12 (25)

6 (17)

12 (22)

9 (19)

27 (31)

11 (18)

10 (19)

2 (5)

19 (15)

79 (24)

90 (15)

75 (20)

87 (23)

90(12)

73 (19)

Mean (SD)

n

101

n
Global health status

EORTC QLQ-C30

Patients who did not receive NAC

Patients who received neoadjuvant chem-otherarpy (NAC)

Domain/item

Questionnaire

Raw scores for patients who did and did not receive neoadjuvant chemotherapy
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− 0.10

Bloating/flatulence*

− 0.13

Fear of recurrence*
Mental Health Inventory
Satisfaction with life

Fear of Recurrence Scale

Mental Health Inventory

Satisfaction with Life Scale

0.84

0.20

− 0.18

0.08

0.30

Future perspectives

Body image satisfaction*

− 0.23

Urinary symptoms*

0.04

Diarrhea*
− 0.17

0.14

Constipation*

Financial problems*

0.03

− 0.11

Insomnia*
Appetite loss*

0.03

Dyspnea*

A higher score on these domains/items reflects worse quality of life

*

0.10

Nausea/vomiting*
− 0.10

0.06

Fatigue*

Pain*

0.10

− 0.04

Cognitive function
Social function

0.31

Emotional function

Sexual dysfunction*

EORTC QLQ-BLM30

Physical function
− 0.03

0.07

Global health status

EORTC QLQ-C30

Role function

0.08

Domain/item

Standardized regression coefficient, (β)
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Questionnaire

0.351

0.027

0.154

0.075

0.406

0.272

0.001

0.008

0.075

0.684

0.141

0.736

0.251

0.785

0.268

0.281

0.523

0.289

0.680

0.001

0.730

0.407

0.390

P value

NAC associated with better Mental Health Inventory

NAC associated with better future perspectives

NAC associated with fewer urinary symptoms

NAC associated with better emotional function

Interpretation
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Propensity-matched analysis
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16
16

Physical function
Role function
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16
16
16
16
16
16
16
16
16
16
16
15
11
12
12
9
16

Cognitive function
Social function
Fatigue*
Nausea/vomiting*
Pain*
Dyspnea*
Insomnia*
Appetite loss*
Constipation*
Diarrhea*
Financial problems*
Urinary symptoms*
Future perspectives
Bloating/flatulence*
Body image satisfaction
Sexual dysfunction*
Fear of recurrence*
Mental Health Inventory
Satisfaction with life

Fear of Recurrence
Scale

Mental Health
Inventory

Satisfaction with
Life Scale

16

16

16

Emotional function

EORTC QLQBLM30

15

Global health status

EORTC QLQ-C30

Patients with
available data, n

Domain/item

Questionnaire

29 (7)

23 (4)

87 (46)

50 (27)

84 (31)

22 (24)

46 (32)

21 (18)

29 (34)

4 (11)

19 (30)

6 (13)

21 (24)

8 (19)

16 (29)

2 (6)

21 (30

77 (27)

88 (16)

80 (16)

74 (38)

85 (20)

75 (23)

Pre-chemo-therapy,
mean (SD)

27 (8)

23 (5)

79 (15)

56 (28)

75 (32)

17 (19)

47 (30)

19 (20)

23 (32)

4 (11)

31 (23)

23 (26)

25 (23)

21 (24)

11(29)

19 (28)

43 (24)

63 (29)

82 (22)

78 (22)

63 (28)

77 (23)

61 (19)

Post-chemo-therapy,
mean (SD)

−2

0

−8

6

−9

−6

1

−2

−6

0

13

17

4

13

−4

17

22

− 15

−5

−2

− 11

−8

− 13

Mean difference

Author Manuscript

Results of patients who completed assessment pre- and post-chemotherapy

− 5 to 1

− 2 to 1

− 28 to 12

− 15 to 27

− 19 to 1

− 23 to 12

− 14 to 16

− 12 to 7

− 13 to 1

− 6 to 6

− 8 to 33

2 to 31

− 5 to 13

− 2 to 27

− 12 to 3

3 to 30

7 to 37

− 30 to 1

− 15 to 4

− 13 to 9

− 30 to 7

− 21 to 6

− 28 to 1

95% CI for difference

0.3

0.8

0.4

0.5

0.06

0.5

0.9

0.6

0.08

1

0.2

0.03

0.3

0.08

0.3

0.02

0.008

0.06

0.3

0.7

0.2

0.2

0.07

P value

Appetite loss
increased

Nausea increased

Fatigue increased

Interpretation

Author Manuscript

Table 4
Feuerstein et al.
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*
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A higher score on these domains/items reflects worse quality of life

Feuerstein et al.
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